Sanofi plans to transfer a portfolio of 20 mature medicines and three manufacturing sites to Cheplapharm under a proposed strategic partnership, receiving a 26.4% equity stake in Cheplapharm in return.
The companies said the commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027. The manufacturing-site transfers would follow, with the transaction expected to be completed by the third quarter of 2027.
The transaction remains subject to employee information and consultation procedures with employee representatives, regulatory approvals and customary closing conditions.
The three sites proposed for transfer are Csanyikvölgy in Hungary, Jurong in Singapore and Ploërmel in France. The Csanyikvölgy site employs about 400 people, the Jurong site about 100 people and the Ploërmel site about 65 people.
Sanofi and Cheplapharm said employees at the sites would continue their activities under existing employment arrangements and collective agreements.
The companies said Cheplapharm would assume responsibility for the selected medicines and the manufacturing facilities as part of the partnership. The announcement did not identify the full list of 20 medicines.
Cheplapharm said the portfolio includes Lovenox/Clexane, which is manufactured at the transferred facilities. The company said it would take on manufacturing capabilities and expertise associated with that product.
Sanofi said it has worked with Cheplapharm since 2014. The proposed partnership expands on previous acquisitions by Cheplapharm of medicines from Sanofi’s mature-medicines portfolio.
The companies said they will work on transition activities and supply continuity as the portfolio and sites move to Cheplapharm.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!